Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HFDM ) in patients in the ACCORD trial.
Malik ElharramJoao Pedro FerreiraThao HuynhJiayi NiNadia GiannettiSubodh VermaFaiez ZannadAbhinav SharmaPublished in: Diabetes, obesity & metabolism (2021)
The TRS-HFDM discriminates HF-specific risk among people with T2DM. The use of TRS-HFDM to identify those who would maximally benefit from therapies that reduce HF risk warrants evaluation.
Keyphrases
- heart failure
- acute heart failure
- left ventricular
- end stage renal disease
- newly diagnosed
- type diabetes
- ejection fraction
- glycemic control
- cardiovascular disease
- pulmonary embolism
- clinical trial
- prognostic factors
- study protocol
- cardiac resynchronization therapy
- metabolic syndrome
- acute ischemic stroke
- phase iii
- insulin resistance
- breast cancer risk